AB Science's leading compound masitinib is emerging as a potential breakthrough treatment for progressive multiple sclerosis, according to renowned neurologist Professor Patrick Vermersch. The drug's unique mechanism of action, which targets both mast cells and microglia in the innate immune system, could represent a significant advance in treating this debilitating condition.
Understanding the Role of Neuroinflammation
Professor Vermersch, Director of the Graduate School for Biology and Health at the Université de Lille and one of The Most Influential Leaders in Neurology 2025, emphasizes the central role of neuroinflammation in various neurodegenerative disorders. His research indicates that mast cells and microglia, two key components of the innate immune system, act as crucial modulators in the neuroinflammatory process that drives disease progression.
"The pro-inflammatory activity of these cells can serve as a catalyst in the neurodegenerative process," explains Vermersch, highlighting the potential impact of targeting these specific cellular mechanisms in conditions such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease.
Masitinib's Novel Therapeutic Approach
The development of masitinib represents a significant departure from conventional treatment approaches. Through its targeted action on both mast cells and microglia, the drug addresses a fundamental aspect of disease progression that has previously been underexplored in therapeutic development.
Phase IIB/III trials have yielded promising results, demonstrating masitinib's effectiveness in:
- Reducing neuroinflammation
- Slowing disease progression
- Offering potential long-term benefits for patients
Clinical Implications and Future Prospects
The ongoing Phase III confirmatory study, led by Professor Vermersch, is particularly significant given the limited therapeutic options currently available for progressive MS patients. The study aims to further define which patient populations might benefit most from this innovative treatment approach.
AB Science, headquartered in Paris and listed on Euronext Paris, has developed masitinib as part of their protein kinase inhibitor (PKI) portfolio. The company's focus on high unmet medical needs positions this development as particularly significant in the field of neurology.
